Src family kinase inhibitors block translation of alphavirus subgenomic mRNAs by Broeckel, Rebecca et al.
Src Family Kinase Inhibitors Block Translation of Alphavirus
Subgenomic mRNAs
Rebecca Broeckel,a Sanjay Sarkar,c Nicholas A. May,d Jennifer Totonchy,a* Craig N. Kreklywich,a Patricia Smith,a Lee Graves,d
Victor R. DeFilippis,a,b Mark T. Heise,c,e Thomas E. Morrison,f Nathaniel Moorman,e Daniel N. Streblowa,b
aVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USA
bDivision of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, Oregon, USA
cDepartment of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
dDepartment of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
eDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
fDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA
ABSTRACT Alphaviruses are arthropod-transmitted RNA viruses that can cause arthral-
gia, myalgia, and encephalitis in humans. Since the role of cellular kinases in alphavirus
replication is unknown, we profiled kinetic changes in host kinase abundance and phos-
phorylation following chikungunya virus (CHIKV) infection of fibroblasts. Based upon the
results of this study, we treated CHIKV-infected cells with kinase inhibitors targeting the
Src family kinase (SFK)–phosphatidylinositol 3-kinase (PI3K)–AKT–mTORC signaling path-
ways. Treatment of cells with SFK inhibitors blocked the replication of CHIKV as well as
multiple other alphaviruses, including Mayaro virus, O’nyong-nyong virus, Ross River vi-
rus, and Venezuelan equine encephalitis virus. Dissecting the effect of SFK inhibition on
alphavirus replication, we found that viral structural protein levels were significantly re-
duced, but synthesis of viral genomic and subgenomic RNAs was unaffected. By measur-
ing the association of viral RNA with polyribosomes, we found that the SFK inhibitor da-
satinib blocks alphavirus subgenomic RNA translation. Our results demonstrate a role for
SFK signaling in alphavirus subgenomic RNA translation and replication. Targeting host
factors involved in alphavirus replication represents an innovative, perhaps paradigm-
shifting, strategy for exploring the replication of CHIKV and other alphaviruses while pro-
moting antiviral therapeutic development.
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Alphaviruses are positive-sense, single-stranded RNA viruses in the Togaviridaefamily, and many of them are transmitted via a bite by infected mosquitoes. Some
alphaviruses cause acute febrile illness and arthritic disease in humans, including
O’nyong-nyong virus (ONNV), Mayaro virus (MAYV), Sindbis virus (SINV), and chikun-
gunya virus (CHIKV) (1–3). The joint and muscle pain caused by CHIKV can be severe (4,
5), and the arthritic pain may last for several months to up to years after acute
symptoms resolve (6, 7). Alphaviruses cause widespread outbreaks in areas of serolog-
ically naive individuals. In 2013, a CHIKV outbreak was initiated in the Caribbean (8),
infecting an estimated 1.9 million people throughout Central and South America
(http://www.paho.org/hq/index.php?optioncom_topics&viewreadall&cid5927&
Itemid40931%3Cen). Other alphaviruses, such as Venezuelan equine encephalitis
virus (VEEV), cause acute febrile illness and neurological disease, including fatal en-
cephalitis (9, 10). In 1995, a VEEV epidemic in Colombia and Venezuela resulted in
75,000 to 100,000 human cases, with a small proportion of those cases developing
encephalitis (11, 12). Treatment of all alphavirus infections, including CHIKV and VEEV,
is currently limited to supportive care. New knowledge of the cellular requirements for
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alphavirus replication should facilitate the development of effective antiviral therapies
to treat individuals suffering from alphavirus infections.
Alphavirus virions are internalized into host cells by clathrin-mediated endocy-
tosis (13, 14), and the glycoproteins initiate viral fusion in endosomal compart-
ments, releasing the viral genome into the cytoplasm. The nonstructural protein
precursors P123 and P1234 are translated from the incoming capped and polyade-
nylated genomic RNA (15, 16). The nonstructural proteins form the replication
complex in spherules at the plasma membrane (17–22). Minus-stranded RNA is
synthesized by P123 and cleaved nsP4, while full-length positive-sense viral
genomic RNA and the subgenomic mRNA (sgmRNA) are synthesized by cleaved
nonstructural protein P1234 (23, 24). The translated subgenomic polyprotein is
cleaved by virus- and host-mediated proteolytic activity into the mature structural
proteins capsid (C), E3, E2, 6K/TF, and E1 (25–27). Translation of the sgmRNA is efficient,
even though CHIKV infection induces inactivating phosphorylation of the  subunit of
eukaryotic translation initiation factor 2 (eIF2) (28). In addition, translation of the SINV
sgmRNA does not appear to require eIF4G (29) or the noncanonical translation initia-
tion factors eIF2D and eIF2A (29, 30). Translation of SINV sgmRNA is facilitated by a
GC-rich structural element called the downstream loop (DLP), which allows for trans-
lation in the absence of eIF2 (28, 31, 32). However, CHIKV and VEEV have no predicted
DLP structure (31), but rather, they may have an alternative mechanism for efficient
sgmRNA translation.
Viruses utilize and modulate cellular signaling pathways to promote an intracellular
environment suitable for viral replication (33, 34) by influencing metabolism, growth,
differentiation, transcription, translation, and cytoskeletal rearrangement (35, 36). One
key group of kinases involved in controlling some of these cellular processes is the Src
family kinases (SFKs) (37–41). Nine Src family kinase members have been described: Src,
Fyn, Yes, Blk, Fgr, Hck, Lck, Yrk, and Lyn. SFKs are myristoylated and sometimes
palmitoylated (42) membrane-associated proteins that mediate signal transduction of
many receptors, including G-protein-coupled receptors (43), receptor tyrosine kinases
(44), and integrins (45). Many viruses encode proteins that directly interact with and
modulate SFK activity (46–49), and therefore, SFK inhibitors have been employed to
study the role of SFKs in virus replication. For example, SFK inhibitors block West Nile
virus (WNV) envelope protein trafficking and maturation (50). The SFK inhibitor dasat-
inib inhibits the replication of dengue virus (DENV) (51, 52), human immunodeficiency
virus (HIV) (53), and hepatitis C virus (HCV) (54). Dasatinib affected multiple stages of
DENV replication by reducing DENV RNA accumulation (52) and preventing virion
assembly in the endoplasmic reticulum (ER) (51). Dasatinib suppressed HIV replication
by blocking reverse transcription and integration (53, 55). In addition, dasatinib was
shown to block HCV fusion during entry by inhibiting ephrin 2A (Eph2A) kinase-
mediated signaling necessary for CD81-CLDN1 cofactor complex formation (54, 56).
Therefore, a precedent exists for utilizing SFK inhibitors to identify steps in viral
replication that require Src-related kinase activity.
Identifying the specific cellular kinases and signaling pathways that promote alpha-
virus replication could aid in the development of antialphavirus compounds. In order
to identify kinase pathways important for alphavirus replication, we profiled changes in
kinase abundance and/or activity following CHIKV infection. We then tested the anti-
viral activities of inhibitors of cellular pathways that were altered by infection, including
the SFK–phosphatidylinositol 3-kinase (PI3K)–Akt–mTOR pathway. SFK inhibitors (PP2
and dasatinib) and mTORC1/2 inhibitors (PP242 and Torin 1) block alphavirus replica-
tion in human fibroblasts. While dasatinib and Torin 1 had minimal effects on viral RNA
(vRNA) synthesis, each treatment blocked structural protein accumulation during CHIKV
and VEEV replication. Furthermore, dasatinib decreased the amount of CHIKV RNA
associated with polysomes, indicating that CHIKV relies on SFKs and mTORC1/2 for
structural protein synthesis. Our novel findings provide insight into molecular processes
that comprise the CHIKV replication cycle, including the requirement of SFK activity for
alphavirus replication.
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RESULTS
Kinome pathway analysis of CHIKV-infected fibroblasts. To identify kinase path-
ways that are kinetically altered following CHIKV infection, we utilized multiplexed
kinase inhibitor beads coupled with quantitative mass spectrometry (MIB-MS) kinome
profiling to quantify changes to the cellular kinome over a time course of infection (57,
58). Kinome profiling uses broad-spectrum kinase inhibitors coupled to a matrix as an
affinity reagent to capture kinases from cell lysates. The identity and abundance of the
recovered kinases are then determined by quantitative mass spectrometry. Changes in
the amounts of kinase recovered under different conditions reflect changes in the
expression or activity of the kinase. As depicted in Fig. 1A, serum-starved normal
human dermal fibroblasts (NHDFs) were infected with CHIKV181/25 (multiplicity of
infection [MOI]  3 PFU/cell), and lysates were collected at 4, 8, 12, and 24 h
postinfection (hpi) for kinome profiling. Infection induced multiple changes to the
kinome (Fig. 1B). Examples of kinases significantly altered after infection are shown in
Fig. 1C. These kinases include the transforming growth factor  (TGF-) receptor
subunits and members of the ephrin family. Other kinases showed consistent trends
but failed to achieve significance due to variability. A comparative analysis of kinome
changes revealed that kinases clustered into three distinct groups by k-means cluster-
ing. Kinases in cluster 1 (118 kinases) remained stable across the course of infection.
Levels of kinases in cluster 2 (32 kinases) were decreased by infection, and those of
kinases in cluster 3 (17 kinases) were increased (Fig. 1D; see also Table S2 in the
supplemental material). These data suggest that CHIKV infection significantly alters the
expression and/or activity of the cellular kinome.
FIG 1 MIBS profiling identifes changes to the cellular kinome induced by CHIKV infeciton. Serum-starved NHDFs were infected with CHIKV (MOI  5 PFU/cell);
harvested at 3, 6, 12, or 18 hpi; and analyzed by MIB-MS kinome profiling. (A) Schematic showing the procedural workflow. (B) Heat map showing average
relative kinase changes (n 3) compared to uninfected cells (0 hpi). Bars to the left of the heat map denote kinase clusters. (C) Examples of kinases significantly
downregulated after CHIKV infection. (D) Graph showing average changes in activity/expression of kinases in clusters 1, 2, and 3.
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Changes in kinase recovery measured by kinome profiling can arise from changes in
either kinase expression or kinase activity due to phosphorylation. To more specifically
identify changes in phosphorylation, CHIKV-infected cell lysates were collected at 0, 1,
2, 4, 6, 8, and 24 hpi and analyzed via PathScan receptor tyrosine kinase (RTK) signaling
antibody arrays spotted with RTK phosphoantibodies (Fig. S1). Increased phosphoryla-
tion of Akt, platelet-derived growth factor receptor (PDGFR), and extracellular signal-
regulated kinase 1/2 (ERK1/2) was detected at early times postinfection (1 to 2 hpi).
Phosphorylation of the ephrins (EphA1, EphB4, and EphB1), Axl, Src, Lck, and IRS-1
occurred after 2 hpi. These findings confirm the kinome profiling results and support
the finding that the SFK-PI3K-Akt-mTOR signaling pathway is activated following CHIKV
infection.
The Src family kinase inhibitor dasatinib blocks CHIKV replication and reduces
CHIKV-induced cell death. Both of the kinome profiling experiments showed that
phosphorylated Src (p-Src) and p-Akt levels change over time during CHIKV infection.
To investigate the functional importance of the SFK-PI3K-Akt-mTOR signaling pathway,
chemical inhibitors of this pathway were tested for their ability to block CHIKV
replication. To ensure that the inhibitors were used at concentrations that were not
cytotoxic, cell viability assays were performed in uninfected NHDFs 24 h after drug
treatment (Fig. S2). Inhibitor activity was verified in NHDFs by Western blotting for the
presence of phosphorylated ribosomal protein S6 (p-rpS6) (Fig. 2C), a common marker
of mTOR activation (59, 60). To assess the effects of the SFK-PI3K inhibitors on CHIKV
replication, NHDFs were pretreated for 2 h with the inhibitor and infected with
CHIKVSL15649 (MOI  1 PFU/cell) in the presence of drug. At 2 hpi, the inoculum was
removed, cells were washed with phosphate-buffered saline (PBS), and new drug-
containing medium was added. Supernatants were collected at 20 hpi, and virus titers
were determined by serial-dilution plaque assays on Vero cells. Dasatinib and Torin 1
treatments reduced yields of infectious virus over 10-fold (Fig. 2A) and reduced
CHIKV-mediated cytotoxicity (Fig. 2B). PP242 and LY294002 treatments mildly reduced
CHIKV yields. In contrast, treatment with GSK 690693, GSK 650394, and CGP 57380 had
no significant effect on CHIKV replication. Treatment with RAD001 and rapamycin
slightly increased CHIKV replication in NHDFs (Fig. 2A), which is consistent with data
from previous reports (61–63).
Of the inhibitors tested, dasatinib treatment resulted in the strongest inhibition of
CHIKV replication. Dasatinib is a potent inhibitor of SFKs (64, 65). As confirmation of this
activity in NHDFs, the activating phosphorylation of Src at Tyr416 was analyzed in cell
lysates at 4, 8, and 24 hpi (66). In the absence of dasatinib, there was an increase of Src
Tyr416 phosphorylation in CHIKV-infected cells compared with uninfected cells. Dasat-
inib reduced Src phosphorylation in both infected and uninfected cells (Fig. 2D).
Dasatinib has many cellular targets, including Src, Lck, Lyn, Yes, Fyn, ephrin recep-
tors, and Bcr/Abl (67). To confirm the importance of Src in CHIKV replication, CHIKV
growth was measured in SYF/ mouse embryonic fibroblasts (MEFs) (lacking Src, Yes,
and Fyn) and Src SYF/MEFs, in which Src was stably reintroduced (68). At each time
point evaluated, yields of infectious CHIKV from Src SYF/ MEFs were consistently
higher than those from SYF/ MEFs at both high and low MOIs (Fig. 3). These data are
consistent with the hypothesis that Src is required for efficient CHIKV replication.
To validate the inhibition of CHIKV replication, immunofluorescence staining was
performed on CHIKV-infected cells treated with dasatinib or another SFK inhibitor, PP2.
Cells were fixed at 24 hpi and stained with antibodies directed against CHIKV E2 and
actin as well as the DNA stain DAPI (4=,6-diamidino-2-phenylindole). Foci of CHIKV-
infected cells were observed in nontreated cells, whereas dasatinib and PP2 treatments
resulted in the presence of single infected cells (Fig. 4). Similar findings were observed
in VEEVTC83-infected cells, where SFK inhibitors blocked the ability of the virus to spread
through the culture (Fig. S3). Combined, these data indicate that SFK inhibitors block
virus spread by reducing infectious virus production from infected cells.
Dasatinib and Torin 1 block alphavirus infection in a type I interferon-
independent manner. CHIKV infection activates interferon (IFN) regulatory factor 3
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FIG 2 Dasatinib (Das), Torin 1, and PP242 block CHIKV replication in human fibroblasts. (A) NHDFs were pretreated for 2 h with drug and infected with
CHIKVSL15649 (MOI 1 PFU/cell). Cells were washed twice with PBS at 2 hpi, and inhibitor-containing medium was added to the cells. Supernatants from infected
cells were collected at 20 hpi, and titers were determined on Vero cells by a limiting-dilution plaque assay. ND, not done. (B) NHDFs were infected with CHIKV
(MOI 3 PFU/cell) and treated with dasatinib at 2 hpi. At 24 hpi, cells were analyzed for viability using the CellTiter-Glo viability assay kit. NI, not infected; DMSO,
dimethyl sulfoxide. (C) NHDFs were treated as described above for panel A, and cell lysates were analyzed by Western blotting for p-S6, S6, and actin. (D) NHDFs
were infected with CHIKV181/25 (MOI  3 PFU/cell) or left uninfected. At 2 hpi, cells were washed twice with PBS, and medium was replaced, with or without
drug. Cell lysates were collected at the indicated times. Western blot membranes were probed with anti-p-SFK (Tyr416) and anti-GAPDH antibodies. Statistics
were performed on log-transformed data, multiple comparisons were performed using Dunn’s multiple-comparison test, and multiplicity-adjusted P values are
reported (n 3) (*, P 0.05; **, P 0.005; ***, P 0.0005; ****, P 0.00005).
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(IRF3), resulting in the transcription of type I interferon, which blocks viral replication
(69). Src can promote the phosphorylation of TANK-binding kinase 1 (TBK1), which
activates IRF3 and promotes type I IFN production (70). Therefore, SFK inhibitors have
the potential to augment CHIKV replication via repression of type I IFN responses. To
test whether dasatinib-mediated inhibition of CHIKV replication was dependent on
IRF3, human fibroblasts deficient in IRF3 (THF-ISRE-ΔIRF3) (71) were infected with
CHIKV181/25 or VEEVTC83 and treated at 0 hpi or 2 hpi with dasatinib. Titers in super-
natants collected at 24 hpi were determined by a serial-dilution plaque assay, and the
results showed that replication of CHIKV and VEEV was inhibited by dasatinib treatment
in IRF3/ cells (Fig. S4A). Another component of the interferon response is the protein
signal transducer and activator of transcription 1 (STAT1), which acts downstream of
the type I interferon receptor and activates the transcription of interferon-stimulated
genes. STAT1 knockout telomerized human fibroblasts (THFs) (THF-ISRE-ΔSTAT1) (71)
were infected with CHIKV181/25 or VEEVTC83 and treated with dasatinib or Torin 1.
Quantification of viral yields at 24 hpi revealed that CHIKV or VEEV maintained sensi-
tivity to dasatinib in STAT1/ THFs (Fig. S4B). Together, these data indicate that the
mechanism of dasatinib and Torin 1 inhibition of CHIKV replication is independent of
their potential effects on IRF3- and STAT1-mediated innate immunity.
Torin 1 and dasatinib differentially regulate autophagy. Autophagy is an important
downstream pathway of mTOR, which is induced when mTOR is inhibited (72). There
are conflicting reports regarding whether CHIKV replication is facilitated or impaired by
autophagy (61, 63, 73), but both Torin 1 and dasatinib block mTOR signaling. Therefore,
we next determined whether Torin 1 and dasatinib treatments induced autophagy in
NHDFs and whether this impacted alphavirus replication. CHIKV181/25-infected cells
were treated with dasatinib, Torin 1, or 3-methyladenine (3-MA) (1 mM), an inhibitor of
autophagy. At 7 hpi, cell lysates were harvested and evaluated by Western blotting to
examine the proteolytic cleavage of LC3-I to LC3-II, a conventional indicator of the
FIG 3 CHIKV replication is suppressed in the absence of Src. SYF/ cells (MEF knockout [K/O] of Src, Yes,
and Fyn) and Src cells (SYF/ cells stably transfected with Src) were infected at an MOI of 5 PFU/cell
(top) or an MOI of 0.5 PFU/cell (bottom); supernatants were collected at 1, 2, and 3 days postinfection;
and titers were determined by a plaque assay. Statistics were performed on log-transformed data and
analyzed by Sidak’s multiple-comparison test, and multiplicity-adjusted P values are reported (n 3) (*,
P 0.05; ***, P 0.0005).
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induction of autophagy (74). Torin 1 induced LC3-II accumulation, but dasatinib and
3-MA did not alter LC3 status compared with untreated infected cells (Fig. S5A). Blotting
cellular lysates for E2 showed that while dasatinib and Torin 1 reduced E2 levels, 3-MA
increased CHIKV E2 accumulation compared with the untreated control (Fig. S5B). Our
data indicate that Torin 1 and dasatinib inhibit CHIKV replication via different mecha-
nisms: Torin 1 may block virus through the induction of autophagy, while dasatinib may
have an alternative mechanism.
Dasatinib does not block CHIKV RNA replication. To further identify the step in
the virus replication cycle sensitive to SFK inhibition, viral RNA (vRNA) accumulation
was monitored in dasatinib- or Torin 1-treated NHDFs infected with CHIKV181/25 or
VEEVTC83 (MOI  3 PFU/cell). Viral RNA levels were measured by reverse transcription-
quantitative PCR (qRT-PCR) at 12 hpi. Dasatinib and Torin 1 modestly reduced CHIKV
RNA levels (Fig. 5A) but had no discernible effect on VEEV RNA accumulation (Fig. 5B).
To validate and further explore the lack of effects of dasatinib on vRNA production, we
performed a Northern blot analysis on RNA isolated from treated NHDFs infected with
CHIKV (MOI  3 PFU/cell). A double-stranded DNA (dsDNA) digoxigenin (DIG)-labeled
probe recognizing E2-6K-E1 was generated to distinguish between genomic vRNA and
subgenomic vRNA. Dasatinib treatment minimally reduced the levels of genomic and
subgenomic CHIKV RNAs to 79% and 98% of the viral RNA levels of the untreated
control, respectively (Fig. 5C). qRT-PCR analysis confirmed that the ratios of CHIKV nsP2
and E2 RNA levels were unaffected by dasatinib treatment (Fig. S6A and S6B). Com-
bined, these data indicate that CHIKV RNA amplification in the presence of dasatinib is
largely unaffected, and the minimal effects on RNA levels could be attributed to the
abrogation of subsequent rounds of replication due to the block in the production of
infectious virus.
Next, we determined whether dasatinib disrupts CHIKV replication complex forma-
tion. At 8 hpi, replication complexes were identified by immunofluorescence staining
with an antibody specific for dsRNA (21, 75). The dsRNA-positive complexes appeared
indistinguishable between dasatinib-treated cells and untreated cells (Fig. 5D). Addi-
tionally, there were no visual differences in the amounts of dsRNA staining at 8 hpi (Fig.
FIG 4 CHIKV replication and spread are limited by dasatinib and PP2. NHDFs were infected with CHIKV181/25
(MOI  1 PFU/cell) and treated with dasatinib or PP2 at 2 hpi. At 24 hpi, cells were fixed, stained for
virus-specific envelope glycoproteins (green), and counterstained with DAPI (blue) and phalloidin (red) to
highlight host DNA and actin filaments.
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S6C), which is consistent with our data demonstrating that dasatinib affects CHIKV
replication downstream of vRNA synthesis.
Dasatinib blocks CHIKV and VEEV structural protein production. We hypothe-
sized that dasatinib does not influence the synthesis of viral nonstructural proteins
since viral RNA levels and replication complex formation appeared normal in treated
cells. To directly test this hypothesis, Western blot analysis for nsP3 was performed on
lysates from treated CHIKV-infected cells at 8 hpi. We observed no difference in nsP3
levels with dasatinib treatment (Fig. 6A) in the presence of a strong reduction in E2
protein accumulation (Fig. 6B). Similarly, levels of VEEV E2 glycoprotein (Fig. 6C) and
capsid (Fig. 6D) were also dramatically reduced in the presence of the dasatinib.
Together, these data suggest that dasatinib blocks the synthesis of alphaviral structural
proteins but has minimal effects on the production of vRNA or nonstructural proteins.
Next, we sought to determine the mechanism by which dasatinib blocks CHIKV
structural protein accumulation. Ribosomal profiling was performed on lysates from
CHIKV-infected, inhibitor-treated NHDFs at 12 hpi. Lysates were fractionated by cen-
trifugation over a linear sucrose gradient, and 17 fractions were collected and analyzed
for the optical density at 264 nm (OD264) as well as for the level of vRNA by qRT-PCR.
FIG 5 SFK inhibitors do not reduce CHIKV RNA synthesis or replication complex formation. (A and B) NHDFs
were infected with CHIKV181/25 (A) or VEEV (B) (MOI  3 PFU/cell). At 2 hpi, cells were washed twice with
PBS, and cells were treated with 10 M dasatinib. At 12 hpi, cells were washed extensively in PBS, and cells
were lysed with TRIzol reagent for total RNA isolation. Relative levels of vRNA were analyzed by qRT-PCR
using gene-specific primers and probes directed against CHIKV E1 and VEEV E2. Statistical analyses were
performed on log-transformed data, data were analyzed by Dunn’s multiple-comparison test, and
multiplicity-adjusted P values are reported (n 3) (*, P 0.05). (C) RNAs from uninfected and CHIKV181/25-
infected cells (MOI  3 PFU/cell) treated with and without dasatinib were analyzed by Northern blotting
for genomic and subgenomic RNA levels at 12 hpi. (D) NHDFs were infected with CHIKV181/25 (MOI  25
PFU/cell) and treated with dasatinib at 2 hpi or left untreated (ND). At 8 hpi, cells were fixed and stained
for dsRNA (J2) (green), actin (phalloidin) (red), and DNA (DAPI) (blue).
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Absorbance readings of the fractions revealed that dasatinib caused an increase of the
absorbance in the 80S monosomal peak and a decrease in the absorbance in polysome
fractions (fractions 9 to 15) (Fig. 7A). In dasatinib-treated cells, the vRNA was shifted into
fractions containing monosomes (Fig. 7B). The translation efficiency (ratio of viral RNA
levels in the polysome fractions to those in the fractions containing ribosomal subunits
and monosomes) was reduced by approximately 80% in dasatinib-treated samples (Fig.
7C). These results indicate that dasatinib treatment disrupted CHIKV structural protein
synthesis by preventing the translation machinery from associating with viral sgmRNA.
Dasatinib does not inhibit alphavirus-mediated host translational shutoff. The
precise mechanism of translation of CHIKV and VEEV sgmRNAs during host transcrip-
tion and translation shutoff is not known (76). Translation of the sgmRNA may not
require many of the canonical translation initiation factors, as was previously docu-
mented for SINV (29, 30, 77). To determine whether dasatinib affects the virus-induced
host translation shutoff process, we performed a puromycin pulse-chase assay in
NHDFs infected with CHIKV or VEEV. Although dasatinib significantly decreased viral E2
accumulation, there was no effect of treatment on virally induced host translation
shutoff at 24 hpi (Fig. 8A). Additionally, dasatinib did not affect puromycin incorpora-
tion into newly synthesized protein in uninfected cells, whereas cycloheximide (CHX)
treatment abolished protein production, and Torin 1 reduced global protein production
(Fig. 8A).
A marker for the shutoff of cellular translation during viral infection is the phos-
phorylation status of the alpha subunit of eukaryotic initiation factor 2 (eIF2), a host
initiation factor essential for the translation of capped mRNAs. Phosphorylation inac-
tivates eIF2, thereby preventing cap-dependent cellular translation. Translation of
CHIKV sgmRNA likely does not require eIF2 because the sgmRNA is translated efficiently
when eIF2 is phosphorylated (69). One of the kinases responsible for eIF2 phosphor-
ylation during CHIKV replication is the cytoplasmic dsRNA sensor protein kinase R (PKR),
which is activated by CHIKV infection (69). Therefore, we determined the effects of
dasatinib and Torin 1 treatments on CHIKV replication in cells lacking PKR. Compared
with the parental cell line, dasatinib and Torin 1 still reduced E2 levels in PKR/ THFs
(Fig. 8B). Consistent with previously reported data, CHIKV infection induced eIF2
phosphorylation in a PKR-dependent manner. In addition, dasatinib treatment in-
FIG 6 Dasatinib blocks structural protein accumulation. (A) NHDFs were infected with CHIKV181/25 (MOI
10 PFU/cell) and treated with dasatinib at 2 hpi, and cell lysates were analyzed for nsP3 protein levels at
8 hpi by Western blotting. (B and C) NHDFs were infected with CHIKV181/25 (B) or VEEVTC83 (C) (MOI  10
PFU/cell), and E2 protein levels were analyzed at the indicated times by Western blotting. (D) For
comparison with another structural protein, NDHFs were infected with VEEVTC83 (MOI  1 PFU/cell),
treated with dasatinib at 2 hpi, and analyzed for VEEV capsid levels by Western blotting.
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creased eIF2 phosphorylation in both the parent THF cell line and PKR/ THFs,
suggesting that dasatinib induces eIF2 phosphorylation in a PKR-independent man-
ner. Since dasatinib induces eIF2 phosphorylation, we tested whether activating
transcription factor 4 (ATF4) levels were affected, as they are expected to increase when
eIF2 is phosphorylated/inactivated (78–80). There was an increase in ATF4 levels
following the addition of dasatinib, suggesting that dasatinib induces a stress response
in the cell. Despite inducing eIF2 phosphorylation and increasing ATF4 levels, dasat-
inib did not have an effect on global protein synthesis, as shown by puromycin
incorporation (Fig. 8A).
We next tested whether dasatinib could block translation from in vitro-transcribed
and capped mRNAs transfected into NHDFs. mRNA was generated by in vitro transcrip-
tion from the CHIKV181/25 cDNA clone or a CHIKV replicon (pMH42), where mCherry
replaces the CHIKV structural genes (Fig. 8C). Transfection of these mRNAs into cells
results in nsP production, replication complex formation, and sgmRNA translation,
leading to mCherry (replicon derived) or the viral structural proteins (cDNA clone
derived). NHDFs were treated with dasatinib, and the production of E2 or mCherry was
quantified at 20 h posttransfection (hpt) by Western blotting. Levels of pE2 were
reduced following dasatinib treatment in mRNA-transfected NHDFs (Fig. 8D), and
mCherry expression was decreased in pMH42-transfected cells, confirming that dasat-
inib blocks the translation of the sgmRNA.
To determine whether dasatinib could block sgmRNA outside the context of the
replicon, another mRNA was generated, which contained the CHIKV 5= subgenomic
untranslated region (sgUTR) followed by a hemagglutinin (HA)-tagged version of
FIG 7 Dasatinib decreases the translation efficiency of CHIKV RNA. (A) NHDFs infected with CHIKV (MOI  3
PFU/cell) were untreated or treated with 10 M dasatinib. Cytoplasmic lysates of infected cells were collected at
12 hpi and resolved through 10 to 50% linear sucrose gradients. The presence of ribosomal subunits (40S and 60S),
monosomes (80S), and polysomes was monitored by continuous measurement of the absorbance (OD254) during
fractionation. (B) Total RNA was prepared from each fraction, and the percentage of CHIKV RNA per fraction was
determined by qRT-PCR as a percentage of the total cytoplasmic viral RNA. (C) The translation efficiency (TE) of
CHIKV RNA under each condition was determined by qRT-PCR. The fold change in translation efficiency for CHIKV
RNA in the presence of dasatinib is reported. The translation efficiency of the vehicle-treated control cells is set to
1 (n 2).
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enhanced green fluorescent protein (eGFP) (sg-HA) (Fig. 8C). mRNAs derived from the
pMH42 mCherry-expressing replicon, sg-HA, or a combination of both were transfected
into NHDFs with and without dasatinib treatment. Consistent with our above-described
data, levels of mCherry generated from the replicon were reduced after treatment with
dasatinib (Fig. 8E). In contrast, samples transfected with sg-HA mRNA demonstrated
increased HA levels in the presence of dasatinib. When both mRNAs were transfected
together, mCherry levels were reduced relative to those with replicon transfection
alone, but expression of mCherry was blocked in the presence of dasatinib, while HA
levels were increased relative to those in untreated cells. These data demonstrate that
FIG 8 Dasatinib blocks translation of sgmRNAs from replicon-containing cells. (A) NHDFs were infected
with CHIKV or VEEV (MOI  10 PFU/cell) or left uninfected. At 2 hpi, cells were treated with 10 M
dasatinib, 250 nM Torin 1, or 200 g/ml cyloheximide (CHX), as indicated. At 8 hpi or 24 hpi, cells were
pulsed with 10 g/ml puromycin (Puro) for 15 min. Following treatment, puromycin-free medium was
added to the cells for 1 h, and lysates were collected and analyzed by Western blotting for puromycin
incorporation and actin. (B) PKR/ THFs or parental THFs were assessed for the presence of PKR and
GAPDH by Western blotting (left). PKR/ THFs or parental THFs were infected with CHIKVSL15649 (MOI 
3 PFU/cell). At 8 hpi, lysates were analyzed by Western blotting for E2, p-eIF2, eIF2, and actin (right).
NHDFs were uninfected or infected with CHIKV and treated with the inhibitor. At 8 hpi or 8 h posttreat-
ment, cell lysates were collected and analyzed for ATF4 and actin by Western blotting (bottom). Rapa,
rapamycin. (C) Schematic of in vitro-synthesized mRNAs. (D) Two micrograms of CHIKV181/25 mRNA or
pMH42 mRNA was transfected into NHDFs and treated with 10 M dasatinib at 45 min posttransfection.
At 20 h posttransfection, cell lysates were analyzed for CHIKV E2, mCherry, or actin by Western blotting.
(E) NHDFs were pretreated with 10 M dasatinib for 30 min prior to transfection or posttreated 30 min
after transfection, as indicated. mRNAs were transfected with 2 g pMH42, sg-HA, or a combination of
both mRNAs. Lysates were collected at 20 h posttransfection and analyzed by Western blotting for
mCherry, HA, and actin.
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dasatinib blocks the translation of sgmRNAs generated from replication-derived com-
plexes but does not block translation of mRNAs outside the context of the viral
replication machinery. However, we cannot rule out the possibility that the effect of
dasatinib on translation is linked to virus-mediated changes in the cellular environment
that may not be fully recapitulated in this system.
Dasatinib and Torin 1, but not rapamycin, block eIF4E phosphorylation. SFKs
modulate a complex array of signaling pathways, including the Raf/MEK/Erk and the
Akt/mTOR pathways (81–83). The Raf/MEK/Erk pathway and p38 mitogen activated
protein (p38 MAP) kinases contribute to activation of eIF4E, which is a rate-limiting
factor in the translation initiation complex of capped mRNAs (84). Figure S7A in the
supplemental material confirms that dasatinib blocks Erk1/2 phosphorylation in NHDFs.
To test whether signaling through the Raf/MEK/Erk/MNK cascade (MNK is mitogen-
activated protein kinase interacting protein kinase) was responsible for the reduction in
viral structural protein synthesis, NHDFs were infected with CHIKV and treated with
U0126, a specific inhibitor of MEK1/2 (85). U0126 reduced the phosphorylation of
Erk1/2, but the treatment failed to affect viral titers or CHIKV E2 protein levels (Fig. S7B).
Similarly, the MNK inhibitor CGP 57380, which blocks eIF4E phosphorylation, did not
block CHIKV replication (Fig. 2A). These results indicate that the dasatinib-mediated
decrease in viral structural protein synthesis is not related to its effects on the
Raf/MEK/Erk signaling pathway.
ONNV, MAYV, and RRV are sensitive to dasatinib and Torin 1.We next examined
the phylogenetic breadth of viruses sensitive to dasatinib and Torin 1. NHDFs were
infected with ONNV, MAYV, or RRV and treated with dasatinib or Torin 1. At 20 hpi, titers
in the supernatants from infected cells were determined by serial-dilution plaque
assays (Fig. 9A). Titers of ONNV, MAYV, and RRV were all significantly reduced by
dasatinib and Torin 1, suggesting a common mechanism of action against a broad
range of alphaviruses. To determine if a more distantly related mosquito-transmitted
RNA virus was also sensitive to dasatinib and/or Torin 1, we tested the ability of these
inhibitors to block the replication of the flavivirus Zika virus (ZIKV). Dasatinib treatment
of ZIKV-infected NHDFs blocked viral replication; however, Torin 1 failed to block ZIKV
infection (Fig. 9B). Consistent with the viral titers, ZIKV E protein levels were reduced by
dasatinib but only moderately decreased by Torin 1. Together, these data indicate that
CHIKV, VEEV, ONNV, RRV, and MAYV are sensitive to both dasatinib and Torin 1.
However, ZIKV exhibits different sensitivities to Torin 1 and dasatinib, indicating a
unique requirement for the Akt/mTOR pathway.
DISCUSSION
Alphaviruses such as CHIKV, VEEV, MAYV, and ONNV are emerging pathogens that
cause severe arthritis or encephalitis. Since there is no FDA-licensed antiviral therapy or
vaccine, there is an urgent need for basic antiviral research to facilitate the creation of
new therapeutics. In this study, we sought to understand the importance of SFK signal
transduction during alphavirus infection. We found that the SFK inhibitor dasatinib and
the mTORC1/2 inhibitor Torin 1 were effective in blocking virus replication at the level
of structural protein synthesis (Fig. 10). Mechanism-of-action studies demonstrated that
both dasatinib and Torin 1 had minimal to no effect on the formation of viral replication
complexes or levels of vRNA. However, both drugs dramatically inhibited viral structural
protein synthesis. Polysome profiling revealed that there were fewer CHIKV viral mRNA
transcripts associated with translation-active ribosomal complexes in dasatinib-treated
cells. These results demonstrate that dasatinib-mediated inhibition of alphaviruses
occurs at a replication stage between viral RNA transcription and structural protein
synthesis.
Dasatinib is a broadly acting SFK inhibitor that affects several cellular processes, and
many of these processes may be required for effective alphavirus replication. We show
that SFK inhibition blocks infection in the absence of functional interferon signaling in
cells lacking IRF3 or STAT1. We also demonstrate that dasatinib, unlike Torin 1, does not
induce autophagy, as indicated by LC3-II accumulation. Interestingly, inhibition of
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autophagy by 3-MA increased E2 accumulation, suggesting that autophagy has a
negative impact on viral replication. Thus, promotion of autophagy by Torin 1 inhibition
may contribute to the impairment of alphavirus translation and replication. These
conclusions contradict other reports using HEK293 cells (61), but these disparities may
reflect differences in cell types. Thus, these results demonstrate that dasatinib-
mediated inhibition of alphavirus replication in human fibroblasts is independent of
interferon signaling and autophagy processes.
We hypothesized that SFK signaling events are required for translation of viral
sgmRNAs. In addition to inhibiting viral structural protein translation during infection,
dasatinib treatment also blocked the translation of replicon-derived sgmRNAs. Impor-
tantly, we show that dasatinib did not inhibit translation of host mRNAs or exogenously
transfected sgmRNAs but that its effects were specific to the replicon-derived sgmRNAs.
These results are reminiscent of those from previous studies with SINV replicons
showing that the translational behavior of transfected subgenomic mRNAs is different
from that of subgenomic mRNAs derived from replicons (86, 87). SINV replicon-derived
sgmRNAs were reported to be translated efficiently in the presence of the eIF4 inhibitor
arsenite, and the replicon-derived sgmRNA had reduced requirements for eIF2, eIF4A,
and eIF4G (29, 77). In contrast, translation of the exogenously transfected sgmRNA was
sensitive to arsenite and required eIF4G. Therefore, we found that dasatinib targets the
translation processes unique to the arsenite-insensitive sgmRNA but not other mRNAs.
During alphavirus infection, translation of host mRNAs is strongly inhibited, while
translation of viral sgmRNAs is very efficient (69, 88, 89). Although host translation
inhibition can occur as a result of virus-induced inactivation of eIF2 by the dsRNA-
FIG 9 Dasatinib inhibits MAYV, ONNV, RRV, and ZIKV replication in NHDFs. (A) NHDFs were infected with ONNV, MAYV, or RRV (MOI 
3 PFU/cell) and treated with the inhibitor at 2 hpi. Supernatants were collected at 24 hpi, and titers were determined on Vero cells
(n 3). (B) NHDFs were infected with ZIKV (MOI 3 PFU/cell) and treated with dasatinib at 2 hpi (n 4). Supernatants were collected
at 48 hpi, and titers were determined on Vero cells. Lystates from infected cells were analyzed for ZIKV E and GAPDH by Western
blotting. Statistical analyses were performed on log-transformed data, data were analyzed by Dunn’s multiple-comparison test, and
multiplicity-adjusted P values are reported (*, P 0.05; **, P 0.005; ***, P 0.0005).
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sensing protein kinase R (PKR), we observed host translation shutoff in PKR/ cells,
where eIF2 is still active, suggesting an alternative mechanism (69, 90). Consistent with
those previous findings, we show that CHIKV induced eIF2 phosphorylation in a
PKR-dependent manner. In addition, dasatinib enhanced eIF2 phosphorylation in
PKR/ and PKR/ cells. eIF2 is phosphorylated by one of four kinases: heme-
regulated inhibitor (HRI), PKR-like endoplasmic reticulum kinase (PERK), general control
nondepressible 2 (GCN2), or PKR (91). As such, dasatinib may induce eIF2 phosphor-
ylation through one of these kinases. One hypothesis based on our results is that the
virus requires eIF2 for its replication and that dasatinib tips the balance of active versus
inactive eIF2 available for the viral sgmRNA. Alternatively, the virus does not require
active eIF2 for translation of its sgmRNA, and dasatinib mediates another effect on the
cell that blocks the synthesis of viral structural proteins.
Previous findings regarding the translation of alphavirus sgmRNA support a
model in which alphaviruses do not require activated eIF2 (28, 32, 92). SINV
possesses a structural element in the 5= end of the sgmRNA called a downstream
loop (DLP), which promotes stalling of the ribosome and negates the need for an
activated eIF2 (28, 31, 32). Other alphaviruses either possess similar DLP structures
with different stabilities and stem lengths or have no predicted DLP-like structure
(31). CHIKV, VEEV, and ONNV do not possess a predicted DLP structure and may
have a different feature that serves the same function. These alphaviruses may have
differential requirements for translation initiation. Conversely, MAYV has a pre-
dicted DLP structure, but it was still sensitive to dasatinib treatment. More exper-
iments are needed to determine whether dasatinib-mediated inhibition of eIF2 is
the mechanism of action for inhibiting translation of the viral sgmRNA or whether
a different feature of translation is blocked.
To identify an SFK-dependent signaling pathway that modulates CHIKV replication,
we utilized a panel of inhibitors specific for downstream molecules of the Ras/Raf/MEK/
ERK and PI3K/Akt/mTORC1 signaling pathways. We show that treatment with U0126, an
inhibitor of MEK1/2, did not affect viral protein synthesis or levels of infectious virus.
This indicated that the effect of dasatinib on viral protein synthesis was mediated by
another signaling event, such as the PI3K/Akt/mTOR pathway. Previous studies found
that mTORC1 inhibition by rapamycin and other rapalogs could enhance CHIKV repli-
FIG 10 Dasatinib and Torin 1 block translation of CHIKV sgmRNA. In this study, we found that CHIKV is sensitive to the SFK
inhibitor dasatinib, the PI3K inhibitor LY294002, and the mTORC1/2 inhibitors Torin 1 and PP242. We show that dasatinib
and Torin 1 block CHIKV sgmRNA translation. In contrast, inhibitors of the Ras/Raf/MEK/ERK pathway did not block CHIKV
sgmRNA translation.
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cation, presumably by enhancing the phosphorylation of eIF4E (62). Rapamycin inhi-
bition of mTOR may result in feedback activation of Akt and increase eIF4E phosphor-
ylation, while PI3K inhibitors and dual mTORC1-mTORC2 inhibitors decrease eIF4E
phosphorylation (93–95). This feedback loop could explain the discordant effects of
Torin 1 and rapamycin treatments on alphavirus replication. We found, however, that
CGP 57380, an MNK1/2 inhibitor that blocks eIF4E phosphorylation, did not block CHIKV
replication, suggesting that eIF4E may not be necessary for translation of the CHIKV
sgmRNA.
Our data indicate that SFK signaling events play a crucial role during alphavirus
replication at the step of structural protein translation but not at the level of viral
RNA synthesis. Therefore, further research on these pathways will facilitate the
development of novel therapeutics that target the translation step of alphavirus
replication and provide insight into the signaling pathways required for efficient
replication.
MATERIALS AND METHODS
Cells. Normal human dermal fibroblasts (NHDFs) (ATCC PCS-201-012), Vero cells (ATCC CCL-81),
Src/Yes/Fyn knockout mouse fibroblasts (68) (SYF/) (ATCC CRL-2459), and SYF/ mouse fibroblasts
reconstituted with Src (SYF c-Src) (ATCC CRL-2498) were grown at 37°C in complete Dulbecco’s
modified Eagle medium (DMEM; Corning) containing 5% or 10% fetal calf serum (Thermo Scientific) and
supplemented with 1 penicillin-streptomycin-glutamine (Life Technologies). Aedes albopictus C6/36
cells (96) (ATCC CRL-1660) were grown at 28°C in complete DMEM. STAT1/ telomerized human
fibroblasts (THF-ISRE-ΔSTAT1), IRF3/ telomerized human fibroblasts (THF-ISRE-ΔIRF3), and PKR/
telomerized human fibroblasts (THF-ISRE-ΔPKR) were generated as previously described and grown
under antibiotic selection (71). Cell viability was assessed using the CellTiter-Glo luminescent cell viability
assay kit (Promega) according to the manufacturer’s instructions.
Viruses. VEEVTC83 was obtained from Michael Diamond (Washington University, St. Louis, MO). ONNV,
MAYV, and RRV were obtained from Robert Tesh (University of Texas Medical Branch, Galveston, TX).
Studies with CHIKV used viruses derived from infectious clones of CHIKV SL15649-pMH56 (97) and
CHIKV181/25 (98) as well as the CHIKV replicon pMH42 (99). Virus stocks were propagated in C6/36 insect
cells by infection at a low multiplicity of infection (MOI). At 48 to 72 h postinfection (hpi), CHIKV, VEEV,
MAYV, ONNV, and RRV stocks were produced by pelleting clarified supernatants through a 15% sucrose
cushion by ultracentrifugation (25,000 rpm [76,618 g] for 1.5 h in an SW 32 Ti rotor). Virus pellets were
resuspended in phosphate-buffered saline and stored at 80°C. PFU for all viral stocks were determined
by serial-dilution plaque assays on Vero cells using a carboxymethylcellulose overlay. At 48 hpi, cells were
fixed with 3.7% formaldehyde and stained with methylene blue, and the plaques were enumerated to
determine virus titers. All MOI calculations were based upon these Vero cell titers. Thus, actual productive
infection levels may vary depending upon the cell type and virus strain used for each experiment.
Kinase inhibitors. Dasatinib, Torin 1, and rapamycin were obtained from LC Laboratories (Boston,
MA). PP242 and RAD001 were obtained from Selleckchem (Houston, TX). PP2, U0126, and GSK 690693
were obtained from Sigma-Aldrich (St. Louis, MO). GSK 650394 was obtained from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA). LY294002 was obtained from Cell Signaling (Danvers, MA). CGP 57380 was
obtained from Abcam (Cambridge, MA).
Kinome profiling. Human dermal fibroblasts were infected with CHIKVSL15649 at an MOI equal to 5
PFU/cell. At 0, 4, 8, 12, and 18 hpi, cells were washed with PBS and then lysed in MIB-MS lysis buffer
(50 mM HEPES [pH 7.5], 150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, 1 mM EGTA, 10 mM NaF, and
2.5 mM NaVO4 plus a protease inhibitor cocktail [Roche], phosphatase inhibitor cocktail 2 [catalog
number P5726; Sigma], and phosphatase inhibitor cocktail 3 [catalog number P0044; Sigma]). Lysates
were sonicated, clarified by centrifugation at 14,000 g, and passaged through a 0.2-m filter. The
protein concentration in each lysate was quantified by the Bradford assay (100). MIB-MS columns
composed of 4 immobilized kinase inhibitors (PP58, purvalanol B, VI16832, and UNC21474) were
equilibrated in MIB-MS high-salt buffer (50 mM HEPES [pH 7.5], 1 M NaCl, 0.5% Triton X-100, 1 mM EDTA,
and 1 mM EGTA) prior to the addition of clarified lysates. MIB-MS columns were washed with MIB-MS
high-salt buffer, MIB-MS low-salt buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 0.5% Triton X-100, 1 mM
EDTA, and 1 mM EGTA), and SDS wash buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 0.5% Triton X-100,
0.1% SDS, 1 mM EDTA, and 1 mM EGTA). Proteins were eluted from the beads by boiling for 15 min in
sample buffer (200 mM Tris-HCl [pH 6.8], 0.5% SDS, 1% -mercaptoethanol). Dithiothreitol (DTT) was then
added to the samples (5 mM final concentration), and the samples were incubated at 60°C for 20 min.
Iodoacetamide was added to a final concentration of 20 mM, and the samples were incubated for 30 min
at room temperature in the dark. Samples were concentrated to a final volume of 100 l using
10,000-molecular-weight (10K)-cutoff Amicon Ultra centrifugal concentrators, and proteins were purified
by methanol-chloroform extraction. Samples were resuspended in 50 mM HEPES (pH 8.0) prior to
digestion with sequencing-grade trypsin (Promega) overnight at 37°C. Residual detergent was removed
by extraction with ethyl acetate, and samples were desalted with C18 spin columns (Pierce) according to
the manufacturer’s protocol. Samples were analyzed by liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) using an Easy nLC 1000 instrument coupled to a QExactive HF mass spectrometer
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(Thermo Scientific). Peptides were separated on an Easy Spray PepMap C18 column over a 2-h gradient
of 5 to 32% mobile phase B at a 250-nl/min flow rate, where mobile phase A was 0.1% formic acid in
water and mobile phase B consisted of 0.1% formic acid in acetonitrile. The QExactive HF mass
spectrometer was operated in the data-dependent mode, and the 15 most-intense precursors peptides
were selected for subsequent MS/MS analysis. To identify kinases, peptide data were analyzed against
the current version of the human UniProt database using MaxQuant software, as previously described
(57, 58). Peptide data are available in Table S1 in the supplemental material. Temporal kinome shifts and
clustering were determined by k-means clustering performed in the R statistical programming language.
Kinase clustering data are presented in Table S2.
Quantitative RT-PCR analysis. Viral RNA in infected NHDFs was quantified using real-time quanti-
tative RT-PCR. Primers and probes include forward primer GAGGTGTGGGACTGGTTGTTG, reverse primer
CAAGTTAGTGCCTGCTGAACGA, and probe AATCGTGGTGCTATGCGT for CHIKV-LR E1; forward primer
CGGCGTCTACCCATTTATGT, reverse primer CCCTGTATGCTGATGCAAATTC, and probe AAACACGCAGTTG
AGCGAAGCAC for CHIKV E1; forward primer AGAGACCAGTCGACGTGTTGTAC, reverse primer GTGCGCA
TTTTGCCTTCGTA, and probe ATCTGCACCCAAGTGTACCA for CHIKV nsP2; and forward primer TCCCGAC
GCCTTGTTCAC, reverse primer CGCCAAAGTCGGATGAATACA, and probe CACCGACACTTTCAGCGG for
VEEVTC83 E2. Total RNA was prepared from infected NHDFs by the TRIzol method at 0, 2, 4, 6, 8, 12, and
24 hpi. RNA was treated with RNase-free DNase, and single-stranded cDNA was then generated using
random hexamers and Superscript III RT (Invitrogen). Gene amplicons served as quantification standards
(the limit of detection is approximately 10 to 100 copies). Quantitative RT-PCR results were analyzed
using an ABI StepOne Plus real-time PCR system (Applied Biosystems).
RNA analysis by Northern blotting. NHDFs were infected with CHIKV181/25, and total RNA was
collected at 12 hpi by the TRIzol method. RNA was electrophoretically separated on a formaldehyde
agarose gel and transferred onto a Hybond-N positively charged nylon membrane (Amersham). CHIKV
RNA was detected using an E2-6K-E1-specific digoxigenin (DIG) probe (Roche) constructed by PCR using
forward primer 5=-CGCAGTTATCTACAAACGGTA-3= and reverse primer 5=-TTTACTCTCAGGTGTGCGA-3=.
Human -actin RNA was detected using a DIG probe constructed using forward primer 5=-ACCCTGAA
GTACCCCATCGA-3= and reverse primer 5=-CGGACTCGTCATACTCCTGC-3=. Detection was performed
using the DIG-High Prime DNA labeling and detection starter kit II (Roche). DIG-labeled membranes
were incubated with a CSPD [disodium 3-(4-methoxyspiro {1,2-dioxetane-3,2=-(5-chloro)tricyclo
(3.3.1.1)decan}-4-yl)phenyl phosphate] alkaline phosphatase chemiluminescent substrate and visualized
on CL-XPosure film (Thermo).
In vitro mRNA synthesis and mRNA transfections. A CHIKV subgenomic mRNA construct express-
ing an eGFP-HA-tagged fusion protein (sg-HA) was generated as follows: the CHIKV 5= sgUTR was
amplified from pMH56 using forward primer 5=-ATATAAGCTTCGTCATAACTTTGTACGGCGG-3= and re-
verse primer (5=-CTCCTCGCCCTTGCTCACCATTGTAGCTGATTAGTGTTTAG-3=. The eGFP-HA fragment was
amplified using forward primer 5=-CTAAACACTAATCAGCTACAATGGTGAGCAAGGGCGAGGAG-3= and re-
verse primer 5=-ATATGGATCCTTAGGCGTAGTCGGGCACATCGTACGGGTACTTGTACAGCTCGTCCATGC-3=.
The sg-HA fusion gene was synthesized by overlapping PCR and cloned into the pSP64 poly(A) vector.
For vRNA synthesis, the CHIKV181/25 cDNA clone and pMH42 were first linearized with NotI (NEB), or
pSP64 was digested with EcoRI (NEB). Capped and polyadenylated mRNA transcripts were generated
from the linearized plasmids using the mMessage mMachine SP6 transcription kit (Thermo Fisher).
Samples were digested with Turbo DNase I, and mRNAs were purified using the RNeasy Plus minikit
(Qiagen). mRNAs were transfected into fibroblasts using Lipofectamine MessengerMAX (Invitrogen)
according to the manufacturer’s instructions.
Protein analysis. Infected cells were washed with ice-cold PBS and lysed with cell lysis buffer (Cell
Signaling) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF; Fisher) on ice for 15 min.
Lysates were collected and centrifuged at 4°C for 10 min at 13,200 rpm. The supernatant was boiled in
Laemmli’s sample buffer and analyzed by SDS-PAGE using 4 to 12% Bis-Tris polyacrylamide gels (Life
Technologies). Proteins were transferred onto polyvinylidene difluoride (PVDF) membranes by semidry
transfer, and the blots were blocked with 5% milk or 5% bovine serum albumin (BSA; Fisher) in
Tris-buffered saline with 0.1% Tween (TBST). Immunoblots were incubated with primary antibodies
directed against CHIKV E2 (obtained from Michael Diamond), nsP3, a -actin–horseradish peroxidase
(HRP) conjugate (13E5), GAPDH (glyceraldehyde-3-phosphate dehydrogenase)-HRP (14C10), pS6 ribo-
somal protein (Ser235/236), S6 (5G10), the p-Src family (Y416), p44/42 Erk1/2 (Thr202/Tyr204), p-4EBP1
(236B4), 4EBP1, p-eIF4E (S209), eIF4E (C46H6), and ATF4 (D4B8) (Cell Signaling); LC3B (Sigma-Aldrich); and
anti-Erk 1 (C-16), anti-LC3B, c-Src (Src2), and PKR (K-17) (Santa Cruz). Antibodies directed against the VEEV
envelope glycoprotein (gp) and VEEV capsid were obtained through BEI Resources, NIAID, NIH, as part
of the Human Microbiome project. Primary antibodies were diluted 1:1,000 in 5% milk in TBST or 5% BSA
and incubated for 1 h at room temperature or overnight at 4°C. The blots were washed with 10 volumes
of TBST and then incubated for 30 min with horseradish peroxidase-linked secondary antibodies diluted
1:10,000 in milk-TBST or BSA-TBST. After washing, the positive bands were detected after the addition of
chemiluminescence reagents and visualized on CL-XPosure film (Thermo).
PathScan RTK antibody array. PathScan RTK signaling phosphoantibody array analysis (Cell Signaling)
was performed according to the manufacturer’s protocol. Briefly, lysates from NHDFs infected with
CHIKVSL15649 at an MOI of 1 PFU/cell were collected at 0, 1, 2, 4, 6, 8, and 24 hpi. Protein concentrations were
normalized, and the samples were incubated on an RTK antibody array chip for 2 h. The plates were washed
and incubated with a detection antibody cocktail for 1 h. The plates were washed and incubated with a
DyLight 680-linked streptavidin secondary antibody, after which they were washed, dried, and scanned using
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an Odyssey infrared imaging system (Li-Cor). Spot intensities were quantified with Odyssey quantification
software and are reported relative to values for the uninfected samples.
Immunofluorescence. Cells were plated onto 4-well Lab-Tek chambered cover glass slides (Fisher)
and infected as indicated. Cells were fixed with 4% paraformaldehyde for 15 min and washed with PBS.
Cells were incubated for 1 h with permeabilization buffer containing 0.2% saponin and 1% BSA. Cells
were incubated overnight, as indicated, with anti-CHIKV E2, anti-VEEV gp, or anti-dsRNA (J2; Scicons)
diluted 1:1,000 in the presence of saponin and BSA. Cells were washed and incubated with goat
anti-mouse Alexa Fluor 488 (Abcam), DAPI, and/or anti-mouse Texas Red-X phalloidin for 1 h. Cells were
washed and visualized using a confocal fluorescence microscope.
Polysome analysis. NHDFs were mock infected or infected with CHIKV181/25 (MOI  3 PFU/cell). At
2 hpi, medium was removed, and cells were washed twice with PBS. The medium was replaced with or
without 10 M dasatinib. At 12 hpi, 0.1 mg/ml cycloheximide (Sigma-Aldrich) was added to the medium,
and cells were incubated for 10 min at 37°C. Following incubation, cells were washed twice with ice-cold
PBS containing 0.1 mg/ml cycloheximide. The cells were scraped, pelleted for 10 min at 1,130 g, and
frozen at 80°C. Samples were resuspended in polysome buffer (20 mM Tris-HCl [pH 7.4], 140 mM KCl,
5 mM MgCl2) containing 0.1% Triton X-100, 10 mM DTT, and 100 M CHX. Cells were disrupted by five
passes through a 27-gauge needle, and nuclei were removed by centrifugation for 5 min at 1,150 g.
The resulting cytoplasmic lysates were layered onto 10 to 50% linear sucrose gradients prepared in
polysome buffer and centrifuged at 35,000 g for 2 h at 4°C with no brake. The gradients were
fractionated with continuous absorbance monitoring at an OD254 using a gradient fractionation system
(Brandel). RNA was isolated from each fraction and quantified by qRT-PCR using the absolute quantifi-
cation method. Translation efficiency was calculated as the sum of CHIKV RNA copies in the polysome-
containing fractions (fractions 9 to 15) divided by the sum of CHIKV RNA copies in the fractions
containing ribosomal subunits and monosomes (fractions 4 to 7) (n 2).
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